Fabian Voß

Fabian Voß

Auto-generated profile, based on publicly available information

Fabian Voß

Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty Heinrich‐Heine University Düsseldorf Düsseldorf Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2023 in Resuscitation
Verified
Journal Article
Closed access
FVFabian Voß
Fabian Voß
TTTharusan Thevathasan
Tharusan Thevathasan
KSKarl Heinrich Scholz
Karl Heinrich Scholz
BBBernd W. Böttiger
Bernd W. Böttiger
DSDaniel Scheiber
Daniel Scheiber
MKMalte Kelm
Malte Kelm

28 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
DDDragos Andrei Duse
Dragos Andrei Duse
MGMichael Gröne
Michael Gröne
NKNicolas Kramser
Nicolas Kramser
MOMatthias Ortkemper
Matthias Ortkemper
CQChristine Quast
Christine Quast
RERalf Erkens
Ralf Erkens
Purpose: Although a moderate proportion of cardiac arrest (CA) patients achieve a return of spontaneous circulation (ROSC), few survive to discharge, mostly with poor neurological development. As serum phosphate levels were described as elevated after cardiopulmonary resuscitation (CPR), we asked whether these elevations would predict a higher risk of mortality and impaired neurological outcome in CA patients following ROSC. Methods: Initial serum phosphate levels, survival, and neurologic status at discharge of 488 non-traumatic CA patients treated at a single German hospital after achieving ROSC were analyzed. The cut-off value of phosphate for mortality prediction was determined using the receiver operator characteristic (ROC) curve, and patients were divided accordingly for comparison. Results were validated by analyzing phosphate levels in a multi-centric cohort containing 3299 CA patients from the eICU database of the United States. Results: In the German cohort, ROC analysis showed a 90% specificity for phosphate levels >2.7 mmol/L to predict mortality (AUC: 0.76, p < 0.0001), and phosphate level elevations were associated with higher in-hospital mortality (crude odds ratio 3.04, 95% CI 2.32 to 4.08). Patients with initial phosphate levels >2.7 mmol/L had significantly higher mortality in both analyzed collectives (p < 0.0001). Similarly, patients from the German cohort who initially had higher phosphate levels also showed a higher proportion of impaired neurological status at discharge and morphological signs of brain injury. Conclusions: In CA patients following ROSC, initial serum phosphate levels >2.7 mmol/L predict higher mortality and impaired neurological outcome. Our data suggests that phosphate determination might improve the preciseness of the overall and neurologic prognostication in patients after CPR following ROSC.

1 January 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
GMGiulia Masiero
Giulia Masiero
FAFederico Arturi
Federico Arturi
SCSara Ceni
Sara Ceni
APAndrea Panza
Andrea Panza
KKKarl-Patrik Kresoja
Karl-Patrik Kresoja
EIEuroTR Investigators
EuroTR Investigators
BACKGROUND: Right heart catheterization plays a pivotal role in the preprocedural evaluation of patients considered for transcatheter tricuspid valve edge-to-edge repair. This study aimed to explore the potential impact of hemodynamic parameters obtained through right heart catheterization on patient-centered outcomes. METHODS: This study represents a subanalysis from the multicenter EuroTR registry (European Registry of Transcatheter Repair for Tricuspid Regurgitation). Patients with invasive hemodynamic data who underwent isolated transcatheter tricuspid valve edge-to-edge repair for significant tricuspid regurgitation were included. Outcomes of interest were a composite of 2-year all-cause death or hospitalization for heart failure (HFH) and a patient-centered composite of 6-month all-cause mortality, HFH, New York Heart Association class IV/worsening New York Heart Association class compared with baseline. Secondary outcome included postprocedural New York Heart Association class improvement. RESULTS: Seven hundred and eleven patients were included in the analysis. Two-year survival free from death and HFH was 63%. Optimal prognostic thresholds identified for death and HFH at 2 years were: mean pulmonary artery pressure≥32 mm Hg, pulmonary capillary wedge pressure (PCWP)≥20 mm Hg, and pulmonary vascular resistance≥5 wood units (WU). The early patient-centered composite outcome occurred in 25% of cases. PCWP≥20 mm Hg was independently associated with an early clinical deterioration (hazard ratio, 2.77 [95% CI, 1.47–5.28]; P <0.001) and with 2-year death/HFH (hazard ratio, 1.75 [95% CI, 1.03–3.02]; P =0.04). No invasive parameter was associated with residual tricuspid regurgitation ≥3+. New York Heart Association class improved significantly throughout the follow-up ( P <0.001), although patients with elevated mean pulmonary artery pressure ( P =0.04) or PCWP ( P <0.01) experienced less symptomatic benefit. CONCLUSIONS: In patients undergoing transcatheter tricuspid valve edge-to-edge repair, invasive hemodynamics—especially elevated PCWP—are independently associated with early patient-centered outcomes and late adverse clinical events. Despite overall improvement of the functional status and no impact on residual tricuspid regurgitation, patients with higher mean pulmonary artery pressure or PCWP benefit less. These findings support the role of comprehensive right heart catheterization in preprocedural risk stratification. REGISTRATION: URL: https://clinicaltrials.gov ; Unique identifier: NCT06307262.

22 May 2024 in JACC: Heart Failure
Verified
Journal Article
Closed access
FVFabian Voß
Fabian Voß
EZElric Zweck
Elric Zweck
RIRojda Ipek
Rojda Ipek
HSHeinz-Peter Schultheiss
Heinz-Peter Schultheiss
MRMichael Roden
Michael Roden
DSDaniel Scheiber
Daniel Scheiber

7 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DODaniel Oehler
Daniel Oehler
CBCharlotte Böttger
Charlotte Böttger
Moritz Benjamin ImmohrMoritz Benjamin Immohr
Moritz Benjamin Immohr
RBRaphael Romano Bruno
Raphael Romano Bruno
JHJafer Haschemi
Jafer Haschemi
UBUdo Boeken
Udo Boeken
Objective: Although the application of higher doses of norepinephrine (NE) in potential organ donors is a frequent reason for heart decline, its associations with outcomes after heart transplantation (HTx) are discussed controversially. Therefore, we aimed to explore donor NE support’s potential impact on outcomes in our single-center heart transplant cohort. Methods: All patients who had undergone HTx in our center between September 2010 and April 2022 (n = 241) were screened for eligibility. From those, all patients with complete data on donor NE support (n = 238) were included. Recipients were divided into three groups according to their donor NE support: without support (n = 26), with low support of 0.01–0.2 µg/kg/min (n = 132), and with high support of > 0.2 µg/kg/min (n = 80). Receiver operating characteristics (ROC) and Kaplan Meier analysis was used to investigate the association of donor NE support and mortality after heart transplantation. Recipient and donor variables, including peri- and postoperative characteristics, were reviewed and compared. Results: NE support in donors ranged between 0 and 2.94 µg/kg/min (median 0.13 µg/kg/min, IQR 0.05–0.26 µg/kg/min). No association between donor NE support and mortality after HTx was observed (AUC for overall survival 0.494). Neither Kaplan-Meier analysis in survival up to 5 years after transplantation (Log Rank p = 0.284) nor group comparisons showed significant differences between the groups. With few exceptions, baseline characteristics in recipients and donors were comparable between the groups. Regarding peri- and postoperative parameters, increasing donor NE support was associated with a longer duration of mechanical ventilation (68 h and 95 h vs. 47 h), longer postoperative IMC/ICU stay (14 vs. 15 vs. 19 days), and a higher need for mechanical life support post-HTx (26% and 39% vs. 12%). Conclusion: In this retrospective analysis, NE support in donors prior to heart transplantation was unrelated to differing survival after heart transplantation. However, higher doses of donor NE were associated with prolonged ventilation, longer duration on IMC/ICU, and a higher need for extracorporeal life support in recipients post-HTx.

13 June 2024 in Clinical Research in Cardiology
Verified
Journal Article
Open access
PDF file
JPJanine Pöss
Janine Pöss
Christoph SinningChristoph Sinning
Christoph Sinning
MRMichelle Roßberg
Michelle Roßberg
NHNadine Hösler
Nadine Hösler
TOTaoufik Ouarrak
Taoufik Ouarrak
TIthe G-CAR Investigators
the G-CAR Investigators
Background: In Europe, more than 300,000 persons per year experience out-of-hospital cardiac arrest (OHCA). Despite medical progress, only few patients survive with good neurological outcome. For many issues, evidence from randomized trials is scarce. OHCA often occurs for cardiac causes. Therefore, we established the national, prospective, multicentre German Cardiac Arrest Registry (G-CAR). Herein, we describe the first results of the pilot phase. Results: Over a period of 16 months, 15 centres included 559 consecutive OHCA patients aged ≥ 18 years. The median age of the patients was 66 years (interquartile range 57;75). Layperson resuscitation was performed in 60.5% of all OHCA cases which were not observed by emergency medical services. The initial rhythm was shockable in 46.4%, and 29.1% of patients had ongoing CPR on hospital admission. Main presumed causes of OHCA were acute coronary syndromes (ACS) and/or cardiogenic shock in 54.8%, with ST-elevation myocardial infarction being the most common aetiology (34.6%). In total, 62.9% of the patients underwent coronary angiography; percutaneous coronary intervention (PCI) was performed in 61.4%. Targeted temperature management was performed in 44.5%. Overall in-hospital mortality was 70.5%, with anoxic brain damage being the main presumed cause of death (38.8%). Extracorporeal cardiopulmonary resuscitation (eCPR) was performed in 11.0%. In these patients, the in-hospital mortality rate was 85.2%. Conclusions: G-CAR is a multicentre German registry for adult OHCA patients with a focus on cardiac and interventional treatment aspects. The results of the 16-month pilot phase are shown herein. In parallel with further analyses, scaling up of G-CAR to a national level is envisaged. Trial registration ClinicalTrials.gov identifier: NCT05142124.